nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2023-2-114-119nnp-2003Research ArticleREVIEWSОБЗОРЫEfficacy and safety of aceclofenac in musculoskeletal diseasesЭффективность и безопасность применения ацеклофенака при скелетно-мышечных заболеванияхhttps://orcid.org/0000-0001-6440-8636ИсайкинаМ. А.IsaikinaM. A.

Кафедра факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского 

119435, Москва, ул. Большая Пироговская, 6, стр.1

Department of the faculty therapy №1, N.V. Sklifosovsky Institute of Clinical Medicine 

6, Bolshaya Pirogovskaya St., Build. 1, Moscow 119435

isaykina_m_a@staff.sechenov.ruhttps://orcid.org/0000-0003-4950-144XИсайкинА. И.IsaikinA. I.

Кафедра нервных болезней и нейрохирургии Института клинической медицины им. Н.В. Склифосовского 

119435, Москва, ул. Большая Пироговская, 6, стр.1

Department of Nervous Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine 

11, Rossolimo St., Build. 1, Moscow 119021

https://orcid.org/0000-0002-7384-6715АхмеджановаЛ. Т.AkhmedzhanovaL. T.

Кафедра нервных болезней и нейрохирургии Института клинической медицины им. Н.В. Склифосовского 

119435, Москва, ул. Большая Пироговская, 6, стр.1

Department of Nervous Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine 

11, Rossolimo St., Build. 1, Moscow 119021

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaRussian Federation202330042023152114119Copyright © Isaikina M.A., Isaikin A.I., Akhmedzhanova L.T., 20232023Исайкина М.А., Исайкин А.И., Ахмеджанова Л.Т.Isaikina M.A., Isaikin A.I., Akhmedzhanova L.T.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/2003

Musculoskeletal system pathology is one of the main causes of morbidity and disability worldwide. Inflammation plays the leading role in the genesis of these diseases. Pain is the most important factor leading to a critical decrease in the quality of life and limitation of daily activities. Most current international guidelines for the treatment of acute and chronic low back and neck pain, osteoarthritis, rheumatoid arthritis and other diseases recommend oral non-steroidal anti-inflammatory drugs as first-line therapy. The article presents data from the latest domestic and international studies, including the results of the largest SOS study, which demonstrated the high efficacy and safety of aceclofenac (Aertal) in acute and chronic neck and back pain.

Патология опорно-двигательного аппарата является одной из основных причин заболеваемости и инвалидности во всем мире. В генезе данных заболеваний ведущую роль играет воспаление. Боль – важнейший фактор, приводящий к резкому снижению качества жизни и ограничению повседневной активности. В большинстве современных международных руководств по лечению острой и хронической боли в пояснице и шее, остеоартрита, ревматоидного артрита и других заболеваний пероральные нестероидные противовоспалительные препараты рекомендуются в качестве терапии первой линии. В статье представлены данные последних отечественных и международных исследований, включая результаты крупнейшего исследования SOS, в которых продемонстрирована высокая эффективность и безопасность применения ацеклофенака (Аэртала) при острой и хронической боли в шее и спине.

боль в спинескелетно-мышечные заболеванияостеоартритревматоидный артритнестероидные противовоспалительные препаратыацеклофенакАэрталэффективностьбезопасностьпроект SOSback painmusculoskeletal diseasesosteoarthritisrheumatoid arthritisnon-steroidal anti-inflammatory drugsaceclofenacAertalefficiencysafetySOS projectReferencesCamilloni A, Nati G, Maggiolini P, et al. Chronic non-cancer pain in primary care: an Italian cross-sectional study. Signa Vitae. 2021;17(2);54-62. doi: 10.22514/sv.2020.16.0111Camilloni A, Nati G, Maggiolini P, et al. Chronic non-cancer pain in primary care: an Italian cross-sectional study. Signa Vitae. 2021;17(2);54-62. doi: 10.22514/sv.2020.16.0111Malik KM, Beckerly R, Imani F. Musculoskeletal Disorders a Universal Source of Pain and Disability Misunderstood and Mismanaged: A Critical Analysis Based on the U.S. Model of Care. Anesth Pain Med. 2018 Dec 15;8(6):e85532. doi: 10.5812/aapm.85532Malik KM, Beckerly R, Imani F. Musculoskeletal Disorders a Universal Source of Pain and Disability Misunderstood and Mismanaged: A Critical Analysis Based on the U.S. Model of Care. Anesth Pain Med. 2018 Dec 15;8(6):e85532. doi: 10.5812/aapm.85532Dalys GBD, Collaborators H. Global, regional, and national disability-adjusted lifeyears (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1260-344. doi: 10.1016/S0140-6736(17)32130-XDalys GBD, Collaborators H. Global, regional, and national disability-adjusted lifeyears (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1260-344. doi: 10.1016/S0140-6736(17)32130-XRicciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31(5):986-1000. doi: 10.1161/ATVBAHA.110.207449Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31(5):986-1000. doi: 10.1161/ATVBAHA.110.207449Atchison JW, Herndon CM, Rusie E. NSAIDs for musculoskeletal pain management: current perspectives and novel strategies to improve safety. J Manag Care Pharm. 2013 NovDec;19(9 Suppl A):S3-19.Atchison JW, Herndon CM, Rusie E. NSAIDs for musculoskeletal pain management: current perspectives and novel strategies to improve safety. J Manag Care Pharm. 2013 NovDec;19(9 Suppl A):S3-19.Косивцова ОВ, Вахнина НВ. Фармакологические и нефармаколо гические методы лечения боли в спине. Эффективная фармакотерапия. 2022;18(5):22-8. doi: 10.33978/2307-3586-2022-18-5-22-28Kosivtsova OV, Vakhnina NV. Pharmacological and non-pharmacological methods of treating back pain. Effektivnaya farmakoterapiya. 2022;18(5):22-8. doi: 10.33978/2307-3586-2022-18-5-22-28 (In Russ.).Парфенов ВА, Парфенова ЕВ. Персонализированный подход к ведению пациентов с хронической неспецифической болью в спине. Медицинский совет. 2022;(11):48-53. doi: 10.21518/2079-701X2022-16-11-48-53Parfenov VA, Parfenova EV. A personalized approach to the management of patients with chronic nonspecific back pain. Meditsinskiy sovet = Medical Council. 2022;(11):48-53. doi: 10.21518/2079-701X2022-16-11-48-53 (In Russ.).Головачева АА, Головачева ВА, Парфенов ВА. Кинезиотерапия и нестероидные противовоспалительные препараты при неспецифической люмбалгии. Неврология, нейропсихиатрия, психосоматика. 2022;14(1):89-96. doi: 10.14412/2074-2711-2022-1-89-96Golovacheva AA, Golovacheva VA, Parfenov VA. Kinesiotherapy and non-steroidal anti-inflammatory drugs for nonspecific lumbago. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(1):89-96. doi: 10.14412/2074-2711-2022-1-89-96 (In Russ.).Насонова ТИ, Парфенов ВА, Мухаметзянова АХ. Типичная врачебная практика ведения пациентов с фибромиалгией. Consilium Medicum. 2022;24(11):796-99. doi: 10.26442/20751753.2022.11.202013Nasonova TI, Parfenov VA, Mukhametzyanova AKh. Typical practice for managing patients with fibromyalgia. Consilium Medicum. 2022;24(11):796-9. doi: 10.26442/20751753.2022.11.202013 (In Russ.).Головачева ВА, Головачева АА, Парфенов ВА. Ведение пациентов с подострой болью в спине: как эффективно предупредить хронизацию. Неврология, нейропсихиатрия, психосоматика. 2022;14(4):62-7. doi: 10.14412/2074-2711-2022-4-62-67Golovacheva VA, Golovacheva AA, Parfenov VA. Management of patients with subacute back pain: how to effectively prevent chronicity. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(4):62-7. doi: 10.14412/2074-2711-2022-4-62-67 (In Russ.).Парфенов ВА. Лечение острой неспецифической боли в спине, применение витаминов группы В. Неврология, нейропсихиатрия, психосоматика. 2022;14(6):98-102. doi: 10.14412/2074-2711-2022-6-98-102Parfenov VA. Treatment of acute non-specific back pain, the use of group B vitamins. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(6):98-102. doi: 10.14412/2074-2711-2022-6-98-102 (In Russ.).Парфенов ВА, Ламкова ИА. Эффективность кинезитерапии при хронической неспецифической люмбалгии. Анналы клинической и экспериментальной неврологии. 2021;15(3):35-42. doi: 10.54101/ACEN.2021.3.4Parfenov VA, Lamkova IA. Effectiveness of kinesiotherapy in chronic non-specific low back pain. Annaly klinicheskoy i eksperimental'noy nevrologii = Annals of Clinical and Experimental Neurology. 2021;15(3):35-42. doi: 10.54101/ACEN.2021.3.4 (In Russ.).Исайкин АИ, Насонова ТИ. Мышечный фактор в развитии скелетно-мышечной боли. Возможности терапии. Неврология, нейропсихиатрия, психосоматика. 2022;14(2):98-104.Isaikin AI, Nasonova TI. Muscular factor in the development of musculoskeletal pain. Treatment options. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(2):98-104. doi: 10.14412/2074-2711-2022-2-98-104 (In Russ.).Парфенов ВА, Богданов ЭИ, Ласков ВБ и др. Многоцентровое рандомизированное двойное слепое исследование эффективности и безопасности толперизона гидрохлорида пролонгированного высвобождения 450 мг (Мидокалм® Лонг, прием один раз в сутки) и толперизона гидрохлорида 150 мг (прием три раза в сутки) при острой неспецифической боли в нижней части спины. Неврология, нейропсихиатрия, психосоматика. 2021;13(6):14-22. doi: 10.14412/2074-2711-2021-6-14-22Parfenov VA, Bogdanov EI, Laskov VB, et al. Multicenter, randomized, double-blind study of the efficacy and safety of prolonged release tolperisone hydrochloride 450 mg (Mydocalm® Long, once daily) and tolperisone hydrochloride 150 mg (three times daily) for acute non-specific lower back pain. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(6):14-22. doi: 10.14412/2074-2711-2021-6-14-22 (In Russ.).Cawston H, Davie A, Paget MA, et al. Efficacy of duloxetine versus alternative oral therapies: an indirect comparison of randomised clinical trials in chronic low back pain. Eur Spine J. 2013 Sep;22(9):1996-2009. doi: 10.1007/s00586-013-2804-7. Epub 2013 May 18.Cawston H, Davie A, Paget MA, et al. Efficacy of duloxetine versus alternative oral therapies: an indirect comparison of randomised clinical trials in chronic low back pain. Eur Spine J. 2013 Sep;22(9):1996-2009. doi: 10.1007/s00586-013-2804-7. Epub 2013 May 18.Медведева ЛА, Загорулько ОИ, Чурюканов МВ. Применение нестероидных противовоспалительных препаратов для профилактики хронизации послеоперационной боли. Клиническая и экспериментальная хирургия. Журнал им. академика Б.В. Петровского. 2022;10(2):120-5. doi: 10.33029/2308-1198-2022-10-2-120-125Medvedeva LA, Zagorulko OI, Churyukanov MV. The use of non-steroidal anti-inflammatory drugs for the prevention of chronic postoperative pain. Klinicheskaya i eksperimental'naya khirurgiya. Zhurnal imeni akademika B.V. Petrovskogo = Clinical and Experimental Surgery. Petrovsky Journal. 2022;10(2):120-5. doi: 10.33029/2308-1198-2022-10-2-120-125 (In Russ.).Geenen R, Overman CL, Christensen R, et al. EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018 Jun;77(6):797-807. doi: 10.1136/annrheumdis-2017-212662. Epub 2018 May 3.Geenen R, Overman CL, Christensen R, et al. EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018 Jun;77(6):797-807. doi: 10.1136/annrheumdis-2017-212662. Epub 2018 May 3.Qaseem A, Wilt TJ, McLean RM, Forciea MA; Clinical Guidelines Committee of the American College of P. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(7):514-30. doi: 10.7326/M16-2367Qaseem A, Wilt TJ, McLean RM, Forciea MA; Clinical Guidelines Committee of the American College of P. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(7):514-30. doi: 10.7326/M16-2367Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheum. 2020 Feb;72(2):220-33. doi: 10.1002/art.41142. Epub 2020 Jan 6.Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheum. 2020 Feb;72(2):220-33. doi: 10.1002/art.41142. Epub 2020 Jan 6.Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 Jun;76(6):978-91. doi: 10.1136/annrheumdis-2016-210770. Epub 2017 Jan 13.Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 Jun;76(6):978-91. doi: 10.1136/annrheumdis-2016-210770. Epub 2017 Jan 13.Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheum. 2019;71(10):1599-613. doi: 10.1002/art.41042Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheum. 2019;71(10):1599-613. doi: 10.1002/art.41042Ortolan A, Webers C, Sepriano A, et al. Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. Ann Rheum Dis. 2023 Jan;82(1):142-52. doi: 10.1136/ard-2022-223297. Epub 2022 Oct 19.Ortolan A, Webers C, Sepriano A, et al. Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. Ann Rheum Dis. 2023 Jan;82(1):142-52. doi: 10.1136/ard-2022-223297. Epub 2022 Oct 19.Яхно НН, Абузарова ГР, Алексеев ВВ и др. Боль: Практическое руководство. Москва: МЕДпресс-информ; 2022. 416 с. ISBN 978-5-907504-41-7Yakhno NN, Abuzarova GR, Alekseyev VV, et al. Bol': Prakticheskoye rukovodstvo [Pain: A Practical Guide]. Moscow: MEDpressinform; 2022. 416 p. ISBN 978-5-907504-41-7 (In Russ.).Исайкин АИ, Акарачкова ЕС, Исайкина ОЮ и др. Боль в спине. Клинические рекомендации. Санкт-Петербург: ООО «Скифия-принт»; 2021. 80 с. ISBN 978-5-98620-567-0хIsaykin AI, Akarachkova ES, Isaykina OYu, et al. Bol' v spine. Klinicheskiye rekomendatsii [Back pain. Clinical guidelines]. St. Petersburg: LLC “Skifia-print”; 2021. 80 p. ISBN 978-5-98620-567-0 (In Russ.).Амелин АВ, Ахмадеева ЛР, Ачкасов ЕВ и др. Диагностика и лечение скелетно-мышечных (неспецифических) болей в нижней части спины. Клинические рекомендации. Москва; 2021.Amelin AV, Akhmadeeva LR, Achkasov EV, et al. Diagnostika i lecheniye skeletno-myshechnykh (nespetsificheskikh) boley v nizhney chasti spiny. Klinicheskiye rekomendatsii [Diagnosis and treatment of musculoskeletal (nonspecific) pain in the lower back. Clinical guidelines]. Moscow; 2021 (In Russ.).Dooley M, Spencer CM, Dunn CJ. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61(9):1351-78. doi: 10.2165/00003495-200161090-00012Dooley M, Spencer CM, Dunn CJ. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61(9):1351-78. doi: 10.2165/00003495-200161090-00012Yamazaki R, Kawai S, Mizushima Y. A major metabolite of aceclofenac, 4'-hydroxy aceclofenac, suppresses the production of interstitial pro-collagenase/proMMP-1 and pro-stromelysin-1/proMMP-3 by human rheumatoid synovial cells. Inflamm Res. 2000 Mar;49(3):133-8. doi: 10.1007/s000110050571Yamazaki R, Kawai S, Mizushima Y. A major metabolite of aceclofenac, 4'-hydroxy aceclofenac, suppresses the production of interstitial pro-collagenase/proMMP-1 and pro-stromelysin-1/proMMP-3 by human rheumatoid synovial cells. Inflamm Res. 2000 Mar;49(3):133-8. doi: 10.1007/s000110050571Iolascon G, Gimenez S, Mogyorosi D. A Review of Aceclofenac: Analgesic and AntiInflammatory Effects on Musculoskeletal Disorders. J Pain Res. 2021 Nov 30;14:3651-63. doi: 10.2147/JPR.S326101Iolascon G, Gimenez S, Mogyorosi D. A Review of Aceclofenac: Analgesic and AntiInflammatory Effects on Musculoskeletal Disorders. J Pain Res. 2021 Nov 30;14:3651-63. doi: 10.2147/JPR.S326101Patel PB, Patel TK. Efficacy and safety of aceclofenac in osteoarthritis: a meta-analysis of randomized controlled trials. Eur J Rheumatol. 2017;4(1):11-8. doi: 10.5152/eurjrheum.2017.160080Patel PB, Patel TK. Efficacy and safety of aceclofenac in osteoarthritis: a meta-analysis of randomized controlled trials. Eur J Rheumatol. 2017;4(1):11-8. doi: 10.5152/eurjrheum.2017.160080Schattenkirchner M, Milachowski KA. A double-blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clin Rheumatol. 2003;22(2):127-35. doi: 10.1007/s10067-003-0710-9Schattenkirchner M, Milachowski KA. A double-blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clin Rheumatol. 2003;22(2):127-35. doi: 10.1007/s10067-003-0710-9Каратеев АЕ, Погожева ЕЮ, Филатова ЕА и др. Факторы, влияющие на результаты обезболивающей терапии. Результаты российского многоцентрового исследования NOTE (NSAID: открытое исследование эффективности). Терапевтический архив. 2018;90(6):65-73. doi: 10.26442/terarkh201890665-73Karateev AE, Pogozheva EYu, Filatova EA, et al. Factors affecting the results of analgesic therapy. Results of the Russian multicentre study of NOTE (NSAID: Open-label Trial of Efficacy). Terapevticheskiy arkhiv. 2018 Jun 20;90(6):65-73. doi: 10.26442/terarkh201890665-73 (In Russ.).Lapeyre-Mestre M, Grolleau S, Montastruc JL; Association FranНaise des CentresRОgionaux de Pharmacovigilance (CRPV). Adverse drug reactions associated with the use of NSAIDs: a case/noncase analysis of spontaneous reports from the French pharmacovigilance database 2002–2006. Fundam Clin Pharmacol. 2013 Apr;27(2):223-30. doi: 10.1111/j.1472-8206.2011.00991.x. Epub 2011 Sep 20.Lapeyre-Mestre M, Grolleau S, Montastruc JL; Association FranНaise des CentresRОgionaux de Pharmacovigilance (CRPV). Adverse drug reactions associated with the use of NSAIDs: a case/noncase analysis of spontaneous reports from the French pharmacovigilance database 2002–2006. Fundam Clin Pharmacol. 2013 Apr;27(2):223-30. doi: 10.1111/j.1472-8206.2011.00991.x. Epub 2011 Sep 20.Wallace JL. NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. Br J Pharmacol. 2012 Jan;165(1):67-74. doi: 10.1111/j.1476-5381.2011.01509.xWallace JL. NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. Br J Pharmacol. 2012 Jan;165(1):67-74. doi: 10.1111/j.1476-5381.2011.01509.xHuskisson EC, Irani M, Murray F. A large prospective open-label, multicentre SAMM study, comparing the safety of aceclofenac with diclofenac in patients with rheumatic disease. Eur J Rheumatol Inflamm. 2000;17(1):1-7.Huskisson EC, Irani M, Murray F. A large prospective open-label, multicentre SAMM study, comparing the safety of aceclofenac with diclofenac in patients with rheumatic disease. Eur J Rheumatol Inflamm. 2000;17(1):1-7.Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012;35(12):1127-46. doi: 10.1007/BF03261999Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012;35(12):1127-46. doi: 10.1007/BF03261999Legrand E. Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother. 2004;5(6):1347-57. doi: 10.1517/14656566.5.6.1347Legrand E. Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother. 2004;5(6):1347-57. doi: 10.1517/14656566.5.6.1347Schjerning AM, McGettigan P, Gislason G. Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nat Rev Cardiol. 2020 Sep;17(9):574-84. doi: 10.1038/s41569-020-0366-z. Epub 2020 Apr 22.Schjerning AM, McGettigan P, Gislason G. Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nat Rev Cardiol. 2020 Sep;17(9):574-84. doi: 10.1038/s41569-020-0366-z. Epub 2020 Apr 22.Pepine CJ, Gurbel PA. Cardiovascular safety of NSAIDs: Additional insights after PRECISION and point of view. Clin Cardiol. 2017 Dec;40(12):1352-56. doi: 10.1002/clc.22814. Epub 2017 Dec 16.Pepine CJ, Gurbel PA. Cardiovascular safety of NSAIDs: Additional insights after PRECISION and point of view. Clin Cardiol. 2017 Dec;40(12):1352-56. doi: 10.1002/clc.22814. Epub 2017 Dec 16.Moore N. Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update. Drug Saf. 2020 Apr;43(4):301-8. doi: 10.1007/s40264-019-00900-8Moore N. Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update. Drug Saf. 2020 Apr;43(4):301-8. doi: 10.1007/s40264-019-00900-8Arfe A, Scotti L, Varas-Lorenzo C, et al. Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28;354:i4857. doi: 10.1136/bmj.i4857Arfe A, Scotti L, Varas-Lorenzo C, et al. Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28;354:i4857. doi: 10.1136/bmj.i4857Masclee GMC, Straatman H, Arfe A, et al. Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project. PLoS One. 2018 Nov 1;13(11):e0204746. doi: 10.1371/journal.pone.0204746Masclee GMC, Straatman H, Arfe A, et al. Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project. PLoS One. 2018 Nov 1;13(11):e0204746. doi: 10.1371/journal.pone.0204746Schink T, Kollhorst B, Varas Lorenzo C, et al. Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: A multi-country European database study within the SOS Project. PLoS One. 2018 Sep 19;13(9):e0203362. doi: 10.1371/journal.pone.0203362Schink T, Kollhorst B, Varas Lorenzo C, et al. Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: A multi-country European database study within the SOS Project. PLoS One. 2018 Sep 19;13(9):e0203362. doi: 10.1371/journal.pone.0203362Исайкин АИ, Шмидт ТЕ, Шор ЮМ. Цервикальная радикулопатия. Неврология, нейропсихиатрия, психосоматика. 2022;14(5):103-8. doi: 10.14412/2074-2711-2022-5-103-108Isaikin AI, Schmidt TE, Shor YuM. Cervical radiculopathy. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(5):103-8. doi: 10.14412/2074-2711-2022-5-103-108 (In Russ.).

The authors declare that there are no conflicts of interest present.